

MEETING AGENDA			
DIVISION	Iowa Medicaid Quality Improvement Organization (QIO)		
MEETING TITLE	Clinical Advisory Committee (CAC)		
FACILITATOR	Bill Jagiello, DO		
DATE	July 21, 2023	TIME	1:00pm-4:00pm
LOCATION	Zoom Meeting https://telligen.zoom.us/join/mtqDkvH93m9BDRRdf-746T3f8SRBY2		

MEETING OBJECTIVES

The purpose of the CAC is to increase the efficiency, quality, and effectiveness of the Medicaid healthcare system. The CAC provides a process for physician and other healthcare provider contributions to promote quality care, member safety, cost effectiveness and positive physician and provider relations through discussion about Medicaid benefits and healthcare services.

The CAC is charged with recommending clinically appropriate healthcare utilization management and coverage decision to the Department of Health and Human Services (HHS) for the Iowa Medicaid program.

HIPAA Reminder: As a reminder to all members of the public who are presenting during the CAC meeting: Do not provide any personal health information (PHI) regarding a member covered by Iowa Medicaid Insurance that would constitute a violation of Federal HIPAA standards.

MEETING PARTICIPANTS

Name	Organization
<input type="checkbox"/> Elizabeth Matney, Medicaid Director	Iowa Medicaid
<input checked="" type="checkbox"/> Rebecca Curtiss, DHHS Bureau Chief, LTSS and Medical Policy	Iowa Medicaid
<input type="checkbox"/> Paula Motsinger, DHHS Bureau Chief, LTSS and Medical Policy	Iowa Medicaid
<input checked="" type="checkbox"/> Bill Jagiello, DO	Iowa Medicaid
<input checked="" type="checkbox"/> Else Umbreit, PharmD	Iowa Medicaid
<input checked="" type="checkbox"/> Mark Randleman, DO	Iowa Medicaid
<input checked="" type="checkbox"/> Misti Johnson	Iowa Medicaid
<input checked="" type="checkbox"/> Carrie Ortega	Iowa Medicaid
<input type="checkbox"/> Becky Carter	Iowa Medicaid
<input checked="" type="checkbox"/> Cassie Reece	Iowa Medicaid
<input type="checkbox"/> Barb Cox	Iowa Medicaid
<input checked="" type="checkbox"/> Pam Lester	Iowa Medicaid
<input checked="" type="checkbox"/> Diane Morrill	Iowa Medicaid
<input type="checkbox"/> Carrie McFarland	Iowa Medicaid

STATE OF IOWA DEPARTMENT OF
Health AND **Human**
 SERVICES

<input type="checkbox"/> Wendy Lathrop	Iowa Medicaid
<input checked="" type="checkbox"/> Charissa Blinkmann	Iowa Medicaid
<input checked="" type="checkbox"/> Dr. Paul Mulhausen	Iowa Total Care
<input checked="" type="checkbox"/> Dr. Nivedita Krishnan	Amerigroup
<input checked="" type="checkbox"/> Dr. Timothy Gutshall	Molina Healthcare of Iowa
<input type="checkbox"/> Dr. Alexandra Hubbell-Family Practice	Committee Member
<input checked="" type="checkbox"/> Clarice Blanchard, PA-C, Family Practice/ Emergency Medicine	Committee Member
<input checked="" type="checkbox"/> Dr. Dana Danley-Family Practice	Committee Member
<input checked="" type="checkbox"/> Dr. Dennis Zachary-Family Practice	Committee Member
<input checked="" type="checkbox"/> Diana Smith, ARNP-Family Practice	Committee Member
<input checked="" type="checkbox"/> Dr. Polly Ferguson-Pediatric Rheumatology	Committee Member
<input type="checkbox"/> Dr. Stephen Mandler-Psychiatry	Committee Member
<input checked="" type="checkbox"/> Dr. Chitra Reddy-Endocrinology	Committee Member
<input checked="" type="checkbox"/> Dr. Kathleen Lange-Family Practice	Committee Member

AGENDA TOPIC	RESPONSIBLE PARTY
New Business	Dr. Jagiello
Public Comment Period	Guests
Approval of April 21, 2023 Meeting Minutes	Dr. Jagiello
Old Business 1. Continuous Glucose Monitoring Systems, CGMs	Dr. Jagiello
Consent Agenda 1. PAM.Adakveo (crizanlizumab-tmca) 2. PAM.Crysvita (burosumab-twza) 3. PAM.Fasenra (benralizumab) 4. PAM.Krystexxa (pegloticase) 5. MED.Namenda (memantine) for Autism Spectrum Disorder 6. PAM.Nexviazyme (avalglucosidase alfa-ngpt) 7. PAM.Rylaze [asparaginase erwinia chrysanthemi (recombinant) 8. PAM.Sarclisa (isatuximab-irfc) 9. PAM.Uplizna (inebilizumab-cdon) 10. PAM.Yescarta (axicabtagene ciloleucel) 11. DME.Custom Knee Orthotics 12. DME.Enteral Products and Supplies 13. DME.High Frequency Chest Wall Oscillators 14. DME.Medical Foods 15. DME.Pneumatic Compression Devices 16. DME.Strollers and Wheelchairs for Safety 17. DME.Wearable Automated External Defibrillator	Dr. Jagiello

STATE OF IOWA DEPARTMENT OF
Health AND **Human**
 SERVICES

18. LAB.Gene Expression Profiling for the Management of Breast Cancer 19. LAB.Genetic Testing for Lynch Syndrome 20. LAB.Molecular Analysis for Targeted Therapy of Non-Small Cell Lung Cancer 21. LOC.Children's Mental Health Level of Care 22. LOC.Habilitation Eligibility (Non-Financial) 23. SRG.Artificial Disc Replacement 24. SRG.Laser Linear Accelerator Based Stereotactic Radiosurgery 25. SRG.Left Ventricular Assist Device 26. SRG.Reduction Mammoplasty/Mastopexy 27. SRG.Risk Reduction Mastectomy	
---	--

Criteria Review 1. PAM. Fyarro (sirolimus protein-bound particles) *new* 2. PAM. Imjudo (tremelimumab-actl) *new* 3. PAM. Margenza (margetuximab-cmkb) *new* 4. PAM. Monjuvi (tafasitamab-cxix) *new* 5. PAM. Opdualag (nivolumab and relatlimab-rmbw) *new* 6. PAM. Jemperli (dostarlimab-gxly) 7. PAM. Keytruda (pembrolizumab)*in-process* 8. PAM. Kymriah (tisagenlecleucel) 9. PAM. Trodelvy (sacituzumab govitecan-hziy) 10. PAM. Zynlonta (loncastuximab tesirine-lpyl)	Dr. Jagiello
---	--------------

Upcoming Meetings Friday, October 20, 2023 Friday, January 19, 2024 Friday, April 19, 2024 Friday, July 19, 2024	Dr. Jagiello
---	--------------

Adjournment	Dr. Jagiello
--------------------	--------------

Contacts:

Dr. Bill Jagiello, D.O.
 Medical Director
 (515)974-3057
wjagiel@dhs.state.ia.us

Charissa Blinkmann
 Review Assistant
 (515)256-4659
cblinkm@dhs.state.ia.us

Guests wanting to speak during the public comment period should contact Charissa Blinkmann and complete a Disclosure Form, which is available on our webpage:
https://dhs.iowa.gov/ime/about/advisory_groups/clinical-advisory-group

STATE OF IOWA DEPARTMENT OF
Health AND **Human**
SERVICES

Introduction

Dr. Jagiello, Medical Director for IME QIO & Committee Chair, offers the introduction for the quarterly (Q3) Iowa Medicaid Clinical Advisory Committee meeting. Silent roll call proceeded with quorum confirmation.

Notice: Due to an unforeseen technical issue, the Q3 meeting wasn't captured by recording in its entirety.

Announcements

Dr. Mandler's current role and duties have expanded and due to his increased responsibilities, he has needed to resign his position with CAC, as a Committee Member.

Approval of the April 21, 2023 Meeting Minutes

Public Comments

Registered speaker acknowledgements with the opportunity to speak as policy is presented.

1. **Chase Williams**-PharmD, MBA, AAHIVE, Principal Medical Scientist, Gilead, **Trodelvy**
2. **Deb Brugman**-MS, CGC, Foundation Medicine, Inc., **Foundation Medicine testing (FoundationOne CDx and FoundationOne Liquid CDx)**
3. **Emily Beckett**-PharmD, BCPS, Family Medicine Residency Clinical Pharmacist, Broadlawns Medical Center, **CGMs**
4. **Gary Dougherty**-Director, State Government Affairs, American Diabetes Association, **CGMs**
5. **Jason Enders**-PharmD, BCPS, Regional Medical Director, Neuroimmunology, Horizon Therapeutics, **Uplizna**
6. **Marie Frazzitta**-DNP, FNP-c, PNP, MBA, CDCES, Senior Medical Outcomes Manager, Abbott Diabetes Care, **CGMs**
7. **Queentela Benjamin**-MS, MPH Foundation Medicine, Inc., **Foundation Medicine testing (FoundationOne CDx and FoundationOne Liquid CDx)**
8. **Sunny Hirpara**-PharmD, AstraZeneca, Clinical Account Director-Payers, **Fasenra**
9. **Susie Moroney**-PharmD, MS, MCOP, Novartis, **Kymriah** and **Adakveo**, present to answer any questions.
10. **Wendy Mobley-Bukstein**-PharmD, BCACP, CDCES, CHWC, FAPhA, Associate Professor of Pharmacy Practice, Drake University, Primary Health Care Clinic, **CGMs**
11. **Roy Thomas**-PharmD, Dexcom, **CGMs**.
12. **Phillip Masters**-PharmD, Clinical Pharmacist, Lucas County Health Center, **CGMs**.
13. **Gary Parenteau**-National Account Executive/Medicaid, Dexcom, **CGMs**.

Old Business:

I. **Continuous Glucose Monitoring Systems, CGMs:**

Robust discussion took place around CGMs. Presenters were especially interested in the removal of criteria #2 from the medical policy which states: "Multiple blood glucose testes are required daily." The Committee proposed that criteria #2 be removed from the clinical criteria. The motion was approved. Additional discussion centered around

interest in moving CGM DME from a medical benefit to a pharmacy benefit. This has been proposed to Iowa Medicaid Medical Policy and they will be reviewing the issue. The discussion and requests are appreciated; however, it should be noted that changing how DME is administered IS NOT within the scope or responsibility of this Committee's work. Other discussion centered around changing the clinical criteria to permit access to diabetic members who take basal insulin doses once daily, instead of the 3 or more daily injections that are currently required. The Chair appreciated the discussion and requested that additional feedback be sent to Iowa Medicaid for consideration. This policy will be brought back as Old Business at the Q4 meeting in October.

Becki Wedemeier, Iowa Medicaid provided statement regarding the two areas that follow: 1.) The request to transition CGMs from medical to pharmacy benefit and 2.) The CGM Access Accelerator work that will begin shortly at Iowa Medicaid. We are investigating the change of CGM from DME to a pharmacy benefit. Dr. Jagiello has written a proposal to submit to Rebecca Curtiss Bureau Chief. We have been selected to participate in a CGM Access Accelerator Program. This is from the Center for Health Care Strategies, made possible through the support of the Leona and Harry Helmsley Charitable Trust.

All Consent Agenda Items reviewed.

All Criteria Review Items were presented and voted on accordingly.

Kymriah-Else presented the policy. She stated she added the criteria language to the other indications to standardize it. This policy had been reviewed a year ago in April 2023, so she had added the guideline section in with the standard language that describes the NCCN guidelines. Dr. Susie Moroney provided appreciation of the revisions of the policy and thoroughness with the policy updates.

PAM.Adakveo – Dr. Susie Moroney available for any questions. Else commented it was on the Consent Agenda, and updated some references, but no change to the criteria or other language. She had no further comments.

Modifications to the Kymriah policy, first motion to approve by Dr. Zachary. Seconded by Dr. Danley. All approved and the motion carried.

Trodely-Else presented the policy. Added another indication under the breast cancer criteria. Option B (the new indication from February 3rd).

Chase Williams, public comment on this policy. He wants to ensure the metastatic triple negative breast cancer policy reflects the category I NCCN recommendation as well. Else reviewed and confirmed it was updated. First motion to approve by Dr. Ferguson; seconded by Dr. Zachary. All approved and the motion carried.

STATE OF IOWA DEPARTMENT OF
Health AND **Human**
SERVICES

Zynlonta-Else presented the policy. There were no new indications, but she included the new NCCN recommendations she included into the Criteria #1. Under the second Criteria, she added “b. Request is for subsequent therapy in a member with histologic transformation of indolent lymphoma to DLBCL who is not a candidate for transplant;” based on current NCCN recommendations. Finally on Criteria 4, she added an (ECOG) performance status of 2. No questions or discussion requested. First motion to approve by Dr. Ferguson; seconded by Dr. Lange. All approved and the motion carried.

Closing recognition: for Dr. Randleman being recognized as a Medical Director and invited for questions or comments for the CGM policy. Dr. Randleman shared his own experience with using a CGM and the vast improvement in his diabetes management, by the great information it provides, and expanding the resources to get it to each individual patient, will be a cost-effective measure for diabetes management and lessen the need for more expensive ongoing care. He would like to see the restrictions lifted to allow wider patient utilization.

No further comments or questions from the Committee Members or Public.

Closing comments: the announcement on an opening for a new Committee Member, to replace Dr. Mandler, with a candidate who has a general interest in making a contribution to the quality and efficacy of care available to our Medicaid members.

Next meeting is October 20, 2023

Dr. Jagiello adjourned the meeting.